Read More
SpaceX playbook set to fuel China's IPO ambitions but tech gap persists
12-06-2026 17:30 HKT
After record IPO, Musk's SpaceX faces next test in market debut
12-06-2026 17:19 HKT




Mainland vaccine maker Ab&B Bio-Tech has pulled in margin loans of HK$54.8 billion, making its retail tranche 1,057 times oversubscribed as of Monday.
The company plans to offer 33.44 million shares to raise up to HK$520 million.
Ab&B Bio-Tech's offer price ranges from HK$12.90 to HK$15.50 per share. Each board lot comprises 200 shares, requiring a minimum investment of roughly HK$3,131.
It is expected to list on Friday.
Citic Securities (Hong Kong) and CMB International are acting as joint sponsors.
Last year, the company's revenue surged four times, while its net loss narrowed by about 39 percent year-on-year.
STAFF REPORTER
Download The Standard app to stay informed with news, updates, and significant events: